[Teduglutide in Adult Patients with Chronic Intestinal Failure due to Short Bowel Syndrome: Treatment Protocol Based...

Chronic intestinal failure due to short bowel syndrome is a severe and complex disease that requires a specialized multidisciplinary treatment. Parenteral nutrition is the fundamental support in these patients; however, in the long term, complications associated with it may develop that contraindicate its continuity. In this context, an isolated or combined intestinal transplant (liver-intestine) is the last alternative to recover intestinal sufficiency. Since 2012 was introduced in the world, the use of semisynthetic GLP2 peptide, called teduglutide, changed the course and prognosis of this disease. Argentina is the Latin American country with the most experience in the use of this enterohormone, with results comparable to those of other international centers. This article summarizes the expert recommendations for the use of teduglutide in patients with chronic intestinal failure due to short bowel syndrome.